Cocer Peptides fɛ 
a bɛ kalo 1 bɔ
BƐƐRƐ KUNNAFONIW NI FƐRƐW KUNNAFONIW BƐƐ MIN BƐ NI WEBSITE KAN NA, U BƐ KUNNAFONIW FƆLƆ DƆRƆN NI KALANSENW YE.
Fɛn minnu bɛ di nin siti in kan, olu dabɔra ɲininiw dɔrɔn kama in vitro. Sɛgɛsɛgɛli in vitro (latinkan na: *in glass*, o kɔrɔ ye gilasi minɛnw na) bɛ kɛ hadamaden farikolo kɔkan. Nin fura ninnu tɛ furaw ye, Ameriki dumuniko ni furako ɲɛmɔgɔso (FDA) ma sɔn u ma, wa u man kan ka kɛ ka furakɛli bana, bana walima bana si bali, k’a furakɛ, walima k’a furakɛ. A dagalen don kosɛbɛ sariya fɛ ka nin fɛn ninnu don hadamaden walima bagan farikolo la cogo o cogo.
Kuma bɛɛ lajɛlen
GLP-2, n’o ye fura kura ye, o ye jateminɛba sɔrɔ farikoloɲɛnajɛ furakɛli siratigɛ la. O ye diɲɛ kɔnɔ agoniste fila fɔlɔ ye min bɛ glucagon-like peptide-1 (GLP-1) minɛbaga ni glucose-dependent insulinotropic polypeptide (GIP) minɛbaga ye. A ka baarakɛcogo kɛrɛnkɛrɛnnen sababu fɛ, a bɛ GLP-1 ni GIP nɔw ladege, ka sugandi kura di joli sukaro kɔlɔsili ma.
Jaa 1 GLP-2 ka baara kɛcogo hadamaden farikolo kɔnɔ.
Fɛɛrɛ min bɛ Kɛ ni wale ye
Inisɔn ni sukaro bɔli ɲɛnabɔli : GLP-2 bɛ dɔ fara inisɔndiya bɔli kan ani ka sukaro bɔli dɔgɔya cogo la min bɛ bɔ sukaro la. Ni sukaro hakɛ wulila, GLP-2 bɛ pankreyasi beta-cellw bila ka inisɔndiya caman bɔ, o bɛ sukaro tali ni a baara teliya ani ka sukaro hakɛ dɔgɔya a bɛ sukaro bɔli fana bali, ka sugunɛ sukaro bɔli dɔgɔya, ka sukaro hakɛ sabati ka taa a fɛ. Nin sariyasun fila in bɛ dɛmɛ ka joli sukaro hakɛ sabatili sabati, ka joli sukaro hakɛ dɔgɔya kosɛbɛ sunɔgɔ ni dumuni kɔfɛ.
Fasa ni farikolojidɛsɛ sabatili: Nin fura in bɛ se ka fasa sabati, o bɛ kɛ sababu ye ka banabagatɔw ka dumuni dunta dɔgɔya, o la ka u girinya dɔgɔya. Kisɛya dɔgɔyali nafa ka bon kosɛbɛ banabagatɔw ma minnu ka farikoloɲɛnajɛ suguya 2 bɛ u la, barisa a ka ca a la fasa ni inisɔndiya tali bɛ tali kɛ ɲɔgɔn na kosɛbɛ. Ni GLP-2 bɛ girinya dɔgɔya, a bɛ dɛmɛ ka inisɔndiya kɛcogo ɲɛ, o bɛ farikolo kɛ inisɔndiya la ka ɲɛ, o la, a bɛ joli sukaro hakɛ kɔlɔsi ka ɲɛ. Ka fara o kan, farikolojidɛsɛ bɛ dɛmɛ ka gɛlɛyaw dɔgɔya i n’a fɔ dusukunnabana farikoloɲɛnajɛ banabagatɔw la.
Kɔnɔbara lankolonya bilali kɔfɛ : GLP-2 bɛ kɔnɔbara lankolonya bila kɔfɛ, ka dumuni to kɔnɔbara la waati janya ani ka a donni sumaya banakɔtaa fitini na, o bɛ sukaro hakɛ jiginni teliya bali. O nɔ bɛ dɛmɛ ka joli sukaro jiginni sabati, kɛrɛnkɛrɛnnenya la ni dumuni kɔfɛ sukaro hakɛ cayalenba kɔlɔsili ye ka ɲɛ, ka cogoya ɲumanw di joli sukaro hakɛ sabatili ma.
Farikoloɲɛnajɛ taamasiɲɛw ɲɛnabɔli : Ka fara a nɔ kan joli sukaro ni girinya la, GLP-2 bɛ nɔ ɲumanw fana jira tulumafɛnw hakɛ ni farikoloɲɛnajɛ taamasiɲɛ wɛrɛw ɲɛnabɔli la. Dɔgɔtɔrɔso ka sɛgɛsɛgɛliw y’a jira ko a bɛ dɛmɛ ka kolosinsinnanw ni triglycérides hakɛ dɔgɔya, ka farikoloɲɛnajɛ kɛnɛya bɛɛ lajɛlen sabati ani ka dusukun ni jolisiraw banaw farati dɔgɔya ka taa a fɛ sukarodunbanabagatɔw la.
Waleyali
SURPASS ni SURMOUNT furakɛli kalanba minnu kɛra Fase III la, olu dafalenw na, GLP-2 ye joli sukaro kɔlɔsili nafa jira ka tɛmɛ. Ni i ye a suma ni furakisɛ ye, GLP-2 ye dɔ bɔ kosɛbɛ ɛmoɲini A1c (HbA1c) hakɛ la ka sɔrɔ fana a bɛ farikolojidɛsɛ nɔ ɲumanw jira. A nafa ka bon ni GLP-1 minɛbaga agonistew ta ye minnu dagalen don sisan. Kɔrɔbɔli dɔw la, banabagatɔ minnu furakɛra ni GLP-2 ye, olu ye HbA1c hakɛ dɔgɔya kosɛbɛ ani ka u girinya dɔgɔya ka ɲɛ, o b’a jira ka jɛya ko a nafa ka bon ani a ka fisa ni sukarodunbana kunbɛnni ni a girinya kunbɛnni ye.
Jabɛti suguya 2 furakɛli : I n’a fɔ dumuni ni farikoloɲɛnajɛ faralen ɲɔgɔn kan, GLP-2 bɛ furakɛli suguya ɲuman di banabagatɔw ma minnu farikololabɔli suguya 2 bɛ u la. A kɛra furakɛli kelen ye wo, walima ni a ni sukarodunbana fura wɛrɛw faralen don ɲɔgɔn kan, GLP-2 bɛ banabagatɔw ka joli sukaro kunbɛnni ɲɛ kosɛbɛ.
Kuncɛli
Kuma surun na, GLP-2 bɛ nafa jira joli sukaro kɔlɔsili la k’a sababu kɛ a ka baarakɛcogo kɛrɛnkɛrɛnnen ye ani a ka baara kɛcogo ɲuman ye kɛnɛyaso sɛgɛsɛgɛliw la. A tɛ joli sukaro hakɛ dɔgɔya dɔrɔn ka ɲɛ, nka a jɔyɔrɔ ka ɲi fana farikolo girinya kunbɛnni na ani farikoloɲɛnajɛ taamasiɲɛw ɲɛnabɔli la.
Sosow (Sɔrɔyɔrɔw).
[1] Sood A, Kaur P, Syed O, ani a ɲɔgɔnnaw. Fɛnɲɛnɛmafagalanw ladonni jiginni : GLP-2 seko jirali sukarodunbana kunbɛnni na ani a kɔfɛ[J]. Dɔgɔtɔrɔso furakɛli dɔnnikɛlaw ka seginkanni, 2024,17(3):235-246.DOI:10.1080/17512433.2024.2310070.
[2] Wong E, Cope R, Dima L, ani a ɲɔgɔnnaw. GLP-2 : Insulinotropic Polypeptide Dual Glucose-dependent ani Glucagon-like Peptide-1 Agonist ye sukarodunbana suguya 2 furakɛli kama[J]. Ameriki ka furakɛli gafe, 2023,30(1):e26-e35.DOI:10.1097/MJT.0000000000001588.
[3] Kumar D, Harshidha D, Mousigan M, ani a ɲɔgɔnnaw. GLP-2, sukarodunbana ni fasa furakɛli laɲini fila kan[J]. Duniya kɔnɔ, ɲinini kura ni yiriwali gafe, 2022,7:983.DOI:10.5281/zenodo.7420605.
[4] Chavda V. P., Ajabiya J., Teli D., ani a ɲɔgɔnnaw. GLP-2, waati kura min bɛ kɛ ka sukarodunbana ni fasa furakɛ ni laɲini fila ye: A Mini-Review[J]. Molecules, 2022,27(13).DOI:10.3390/molecules27134315. Bamako, Mali.
[5] Forzano I, Varzideh F, Avvisato R, ani a ɲɔgɔnnaw. GLP-2: Kunnafoni kura sigilen don[J]. Duniya kɔnɔ, 2022,23(23).DOI:10.3390/ijms232314631.
Fɛn min bɛ sɔrɔ ɲininiw dɔrɔn kama:
